Guided Therapeutics, Inc. (OTCQB: GTHP) announced it has secured a significant $700,000 purchase order from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva Advanced Cervical Scan systems, marking a major expansion into the Chinese healthcare market. The order represents delivery of systems over the next eight months beginning in July 2025.
Strategic Partnership in High-Volume Market
HDMT operates as the exclusive gynecology products provider for 42 hospitals in Hangzhou City, Zhejiang Province, conducting approximately two million cervical cancer screenings annually. Yang Dongye, CEO of HDMT, expressed strong confidence in the technology, stating: "We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva."
The LuViva systems will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI), while HDMT will order directly from Guided Therapeutics.
Advanced Detection Technology
The LuViva Advanced Cervical Scan utilizes patented biophotonic technology that employs light for early disease detection at the cellular level. The non-invasive device provides instant results at the point of care, offering a rapid and painless testing platform for cervical disease screening.
In multi-center clinical trials involving women at risk for cervical disease, the technology demonstrated the ability to detect cervical cancer up to two years earlier than conventional screening modalities, according to published reports.
Financial Support for Commercialization
In addition to the purchase order, Guided Therapeutics received $100,000 from SMI via its investment partners to assist in commercializing LuViva in China. This payment represents the first of several planned payments that extend GTHP's agreement with SMI for LuViva commercialization in China, contingent on regulatory approval by September 2025.
A portion of these proceeds will supply SMI and its partner distributors in China with electronic components used in LuViva accessories.
Market Impact and Future Outlook
Mark Faupel, CEO of Guided Therapeutics, emphasized the significance of the partnership: "Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI."
The company anticipates making initial shipments to HDMT next month, positioning LuViva to potentially transform cervical cancer screening practices across Zhejiang Province's hospital network.
The LuViva Advanced Cervical Scan remains an investigational device limited to investigational use in the United States under federal law, while the company pursues regulatory approval for commercial use in China.
